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Open access under CC B5-Hydroxymethylcytosine (5hmC) was recently described as a stable modiﬁcation in mammalian DNA.
5hmC is formed by the enzymatic oxidation of 5-methylcytosine (5meC). Overwhelming evidence sup-
ports the notion that 5meC has a negative effect on transcription; however, only recently has the effect
that 5hmC has on transcription begun to be studied. Using model substrates including the CMVIE pro-
moter and a generic gene body we have directly assessed the effect that 5hmC, both at the promoter
and in the gene body, has on in vitro gene transcription. We show that the presence of the 5hmC modi-
ﬁcations strongly represses transcription. We also demonstrate that the inhibition of transcriptional
activity is primarily due to the presence of 5hmC in the promoter and that 5hmC in the gene body has
a minimal effect on transcription. Thus, we propose that the presence of 5hmC in promoter prevents
the binding of essential transcription factors or recruits factors that repress transcription.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Cytosine methylation in mammals occurs primarily at CpG
dinucleotides. Cytosine methylation (5meC) is achieved by the
enzymatic addition of a methyl group to the N5 position of cyto-
sine. This enzymatic addition is speciﬁcally achieved by DNMT1
and DNMT3, which act to maintain DNA methylation or initiate
de novo methylation. The presence of 5meC at gene promoters is
a well-described mechanism of transcriptional regulation. In gen-
eral, cytosine methylation at gene promoters causes a reduction
of transcriptional activity (for a recent review see [1]).
In 2009 two independent laboratories discovered an oxidized
form of 5meC – 5-hydroxymethylcytosine (5hmC) [2,3]. Initially,
this modiﬁcation was shown to be a stable DNA modiﬁcation in
embryonic stem cells and highly specialized Purkinje neurons [2].
This group was also unable to identify 5hmC in cancerous cell lines.
Later, 5hmC was identiﬁed in all mammalian tissue studied [4–6].
Initial reports demonstrated that 5hmC resulted from the, 5-hydroxymethylcytosine;
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Klungland).
Y-NC-ND license.oxidation of 5meC catalyzed by the Tet1 protein [3]. Further re-
search has shown that Tet1, Tet2, and Tet3 are capable of catalyz-
ing the oxidation of 5meC resulting in 5hmC [7].
The 5hmC modiﬁcation in mammalian DNA has been attributed
to many cellular processes. Several reports have shown that 5hmC
may be an intermediate in the oxidative demethylation of 5hmC
[3]. 5hmC has also been implicated in early developmental pro-
grams [8] and necessary for stem cell renewal [7,9,10]. Deﬁciencies
in Tet2 that led to aberrant 5hmC proﬁles have been implicated in
the pathogenesis of certain myeloid tumors [11].
The genomic position of 5hmC suggests that 5hmC is found pri-
marily in the body of the gene [11,12]; however, 5hmC may also be
found in promoter regions [13]. Based upon current reports it has
been suggested that 5hmC located in the gene body enhances tran-
scriptional activity [8]; although, the presence of 5hmC in promot-
ers appears to suppress transcription [9,14]. Some reports have
suggested that 5hmC may relieve the transcriptional repression
afforded by the 5meC modiﬁcation [8,15].
The goal of this report is to directly address the effect that 5hmC
has on transcription. Using an in vitro system we have been able to
directly assess the singular effect that 5hmC has on transcription.
We show, in a deﬁned system, that the presence of 5hmC strongly
suppresses transcription from the CMVIE promoter. We also dem-
onstrate that the inhibition of transcriptional activity is due to
the presence of 5hmC in the promoter. Additionally, we show that
5hmC within a generic gene body has negligible effects on
transcription.
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2.1. DNA substrates
Substrates were created by PCR amplifying the CMVIE promoter
and a generic gene body (sequence and PCR primers in Supplemen-
tal Fig. S1) with primers 1 and 2. Substrates containing 5hmC were
ampliﬁed in the presence of d5hmCTP (Bioline) instead of dCTP.
Substrates containing 5meC were incubated with 10 units M.SssI
methyltransferase (NEB) in the presence of 160 lM S-adenosyl
methylmethionine according to the manufacturer’s instructions.
The substrate containing an unmodiﬁed promoter with a 5hmC
gene body was created by the PCR ampliﬁcation of the promoter
with primers 1 and 3 and the PCR ampliﬁcation of the gene body
with primers 2 and 4 with d5hmCTP in place of dCTP. These PCR
products were puriﬁed on a gel using a gel extraction kit (Qiagen)
followed by digestion with SacI (10 units/lg DNA) at 37 C for 4 h.
Enzymes were removed using a PCR clean kit (Qiagen). Four micro-
grams of 5hmC modiﬁed promoter DNA was ligated to 4 lg of
cytosine gene body by incubation of the two DNA with 15 units
T4 DNA ligase overnight at 16 C. Correctly ligated (1.2 kbp) prod-
ucts were extracted from an agarose gel using a gel extraction kit
(Qiagen).
The substrate containing a 5hmC promoter with an unmodiﬁed
gene body was created by PCR ampliﬁcation of the promoter with
primers 1 and 5 with d5hmCTP in place of dCTP and the PCR am-
pliﬁcation of the gene body with primers 2 and 6. These PCR pro-
ducts were puriﬁed on a gel using a gel extraction kit (Qiagen)
followed by digestion with HindIII (10 units/lg DNA) at 37 C for
4 h. Enzymes were removed using a PCR clean kit (Qiagen). Four
micrograms of 5hmC modiﬁed promoter DNA was ligated to 4 lg
of cytosine gene body by incubation of the two DNA with 15 units
T4 DNA ligase overnight at 16 C. Correctly ligated (1.2 kbp) pro-
ducts were extracted from an agarose gel using a gel extraction
kit (Qiagen).HeLa nuclear extract (µg)
Fig. 1. 5hmC inhibits transcription from the CMVIE promoter. (A) The modiﬁed
bases used in this study. (B) The substrates used for the assay were synthesized as
described in Section 2. (C) Increasing concentrations of HeLa nuclear extracts were
incubated with 100 ng of a DNA substrate that was either unmodiﬁed, 5meC
modiﬁed at CpG sequences, or all the cytosines were replaced with 5hmC, the band
at 383 represents the run-off transcript from each DNA substrate. (D) Quantiﬁcation
of the transcripts synthesized by HeLa nuclear extracts from each substrate, error
bars represent the standard deviation from the mean of at least three assays.
Abbreviations: C: cytosine, 5meC: 5-methylcytosine, 5hmC: 5-hydroxymethylcyto-
sine.2.2. In vitro transcription reactions
Reactions (25 ll) containing 12 mM HEPES pH 7.9, 12% (v/v)
glycerol, 0.3 mM dithiothreitol (DTT), 0.12 mM EDTA pH 8.0,
60 mM KCl, 3 mM MgCl2, 0.4 mM ATP, 0.4 mM CTP, 0.4 mM UTP,
16 lM GTP, 10 lCi a-[32P]-GTP, and 100 ng of DNA substrates as
described above were initiated by the addition various concentra-
tions of HeLa nuclear extract (Promega) and incubated at 30 C for
60 min. The reactions were terminated by the addition of 175 ll of
a solution containing 0.3 M Tris–HCl pH 7.4, 0.3 M sodium acetate,
0.5% (w/v) sodium dodecyl sulfate, 2 mM EDTA pH 8.0 and 3 lg/ml
tRNA. RNA was extracted by phenol:chloroform extraction and
ethanol precipitated. RNA pellets were dissolved in 98% formamide
and electrophoresed on 6% (w/v) acrylamide gels containing 7 M
urea. Electrophoresis continued until the bromophenol blue dye
ran off the gel and exposed to a phosphorimaging screen. Results
from each assay were normalized to the lowest concentration of
nuclear extract using the substrate that contained unmodiﬁed
cytosine.3. Results
Recent reports have suggested that 5hmC may enhance or be
inhibitory to transcription. The enhancement or inhibition of tran-
scription by 5hmC has been attributed to the location of 5hmC
either within the gene body or gene promoter, respectively [8–
10,14,15]. We endeavored to elucidate the effect that 5hmC has
on transcription using an CMVIE promoter and a generic gene bodywhich allowed us to determine the precise effects that 5hmC has
on transcription (Fig. 1A and B).
3.1. The presence of 5hmC in DNA inhibits transcription
We evaluated transcription activity using run-off transcription
in HeLa nuclear extracts from the cytomegalovirus immediate early
promoter (CMVIE) followed by a 383 base pair sequence (Supple-
mental Fig. S1). Substrates were created using the DNA backbone
shown in Fig. 1A that were either completely unmodiﬁed, 5meC
modiﬁed at CpG regions, or every cytosine replaced with 5hmC
(Fig. 1B). These substrates were incubated with increasing amounts
of HeLa nuclear extracts. After incubation run off transcripts were
isolated and identiﬁed using denaturing PAGE. Relative transcrip-
tion was quantiﬁed as described in Section 2. After quantiﬁcation
we show that in a concentration dependent manner nuclear ex-
tracts from HeLa cells efﬁciently support transcription from the
substrates that contain unmodiﬁed cytosines and, as expected, low-
er levels of transcription from DNA that contained 5meC modiﬁed
at CpG regions. However, HeLa nuclear extracts were poorly able
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Repressor3.2. 5hmC at the promoter and not in the gene body inhibits
transcription
The above result strongly supports the hypothesis that the
presence of 5hmC inhibits transcription; however, we wanted to
address whether the presence of 5hmC in the promoter or in the
gene body is inhibitory to transcription. To address this issue we
designed hybrid substrates that contained cytosine in the pro-
moter and 5hmC in place of cytosine in the gene body or 5hmC
in place of cytosine in the promoter and cytosine in the gene body
(Fig. 2A). These substrates were incubated with increasing
amounts of HeLa nuclear extracts and the amount of run off
transcript was quantiﬁed as described in Section 2. After quantiﬁ-
cation the substrate that contained 5hmC at the promoter with an
unmodiﬁed gene body showed almost no run-off transcript
whereas the substrate with an unmodiﬁed promoter and 5hmC
in the gene body showed signiﬁcantly higher levels of transcription
(Fig. 2B and C). However, the levels of transcription from the
unmodiﬁed promoter with a 5hmC gene body produced transcripts
that were about three fold lower than substrates that contained
only cytosine (Figs. 1D and 2C). These results support the notionC 5hmC5hmC C
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Fig. 2. 5hmC at the promoter is inhibitory to transcription. (A) The C promoter/
5hmC gene body substrate represents an unmodiﬁed promoter with a 5hmC
modiﬁed gene body; the 5hmC promoter/C gene body represents a substrate with a
5hmC modiﬁed promoter with an unmodiﬁed gene body. Substrates were
synthesized as described in Section 2. (B) Increasing concentrations of HeLa nuclear
extracts were incubated with 100 ng of the C promoter/5hmC gene body DNA
substrate or the 5hmC promoter/C gene body DNA substrate, the band at 383
represents the run off transcript from each DNA substrate. (C) Quantiﬁcation of the
transcripts synthesized by HeLa nuclear extracts from each substrate. Error bars
represent the standard deviation from the mean of at least three assays. Abbre-
viations: C: cytosine, 5meC: 5-methylcytosine, 5hmC: 5-hydroxymethylcytosine.
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Fig. 3. Models representing the potential mechanisms of transcriptional inhibition
from promoters that contain 5hmC modiﬁcations. (A) 5hmC at the promoter
prevents the binding of basal transcription factors or RNA polymerase II effectively
suppressing transcription. (B) 5hmC recruits another cellular factor(s) that prevents
some or all of the transcription machinery from binding to the promoter
suppressing transcription. (C) 5hmC at a gene promoter may allow for the basal
transcription machinery to bind to the promoter; however, the 5hmC induces a
conformational change in the basal transcription factors or recruits another protein
that prevents the release of RNA polymerase II from the promoter inhibiting
transcription initiation.that 5hmC in promoters is inhibitory to gene transcription whereas
5hmC in the gene body does not directly inhibit transcription.
However, 5hmC in the gene body does appear to reduce transcrip-
tion, perhaps by reducing the transcription rate of RNA polymerase
II. Additionally, this data suggests that 5hmC within the gene body
does not by itself increase transcription.4. Discussion
The effect that 5meC has on transcriptional regulation has been
extensively studied; however, the effect that 5hmC has on tran-
scription has only been indirectly addressed [8–10,14]. We aimed
to directly evaluate the effect that the presence of 5hmC has on
in vitro transcription using the CMVIE promoter and a generic gene
body in a well-deﬁned mammalian system.
In this report we have directly demonstrated that the presence
of 5hmC at the CMVIE promoter strongly inhibits transcription in
human nuclear extracts. This ﬁnding is not surprising given that
two groups have indirectly shown that the presence of 5hmC at
gene promoters reduces gene expression [10,14]. We also demon-
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effects on transcription in this in vitro system, contrasting with a
previous report that suggests that 5hmC in the gene body increases
transcription [8]. We have previously shown that the presence of
5hmC at the promoter may differentially affect gene transcription
[13]. These previous studies used a less well-deﬁned system that
likely had 5hmC-modiﬁed DNA in association with histones that
may, themselves, differentially affect transcription in the presence
of 5hmC. The presence of histones in these studies makes it difﬁ-
cult to isolate singular function of 5hmC on gene transcription.
The aim of our study was intended to measure the direct effect that
the presence of 5hmC has on transcription in the promoter and/or
in the gene body in the absence of nucleosomes. Demonstrating
that 5hmC in the gene body has a limited effect on transcription
is important because this ﬁnding rules out that 5hmC provides
an elongation block to RNA polymerase II. Therefore, we can
conclude that elongation catalyzed by RNA polymerase II is not
inhibited by the presence of 5hmC and thus 5hmC prevents
transcriptional initiation.
We propose that the inhibition of transcription initiation from a
gene that has 5hmC at its promoter may occur by three different
mechanisms. First, the 5hmC at the promoter may directly prevent
the binding of necessary transcription factors or RNA polymerase II
from binding to the DNA preventing the formation of the
pre-initiation complex (Fig. 3A). Secondly, 5hmC may recruit an
unknown factor to the promoter that inhibits the binding of basal
transcription factors or RNA polymerase II (Fig. 3B). Currently, we
are designing assays to assess the mechanism by which this
transcriptional inhibition is carried out. Finally, 5hmC at the
promoter may allow for the binding of the basal transcription
factors and RNA polymerase II; however, 5hmC may provide an
inhibitory signal to the pre-initiation complex preventing the initi-
ation of transcription despite the presence of the all the necessary
transcription factors and RNA polymerase II (Fig. 3C).
In summary, we have directly demonstrated that 5hmC located
in the promoter region provides a signiﬁcant inhibition to tran-
scription. This inhibition is likely caused by 5hmC interfering with
the assembly of the transcriptional pre-initiation complex or inhib-
iting the pre-initiation complex from releasing RNA polymerase II
starting gene transcription.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbrc.2011.06.077.References
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